MPLT

MapLight Therapeutics, Inc.

• Seeking Alpha·10/28 15:26

  MapLight: 'Hold' Rating On ML-007C-MA In Schizophrenia And 2nd Half 2027 ADP Data Readout

• Seeking Alpha·10/06 11:52

  MapLight co-founder is joint winner of 2026 Nobel Prize in Medicine

• Dow Jones·10/06 11:33

  MapLight Therapeutics Initiated at Neutral by Guggenheim

• Dow Jones·10/06 11:00

  Press Release: MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics

• TipRanks·10/05 20:15

  MapLight Therapeutics initiated with a Neutral at Guggenheim

• Dow Jones·09/29 17:54

  MapLight Therapeutics Currently Down 11 Consecutive Days, on Pace for Record Losing Streak -- Data Talk

• Dow Jones·09/24 16:56

  MapLight Therapeutics on Track for Record Losing Streak -- Data Talk

• TipRanks·09/09 21:30

  MapLight Therapeutics files to sell 13.18M shares of common stock for holders

• TipRanks·08/31 11:15

  MapLight Therapeutics price target lowered to $43 from $45 at Needham

• Dow Jones·08/31 10:15

  MapLight Therapeutics Is Maintained at Buy by Needham

• Dow Jones·08/31 10:15

  MapLight Therapeutics Price Target Cut to $43.00/Share From $45.00 by Needham

• TipRanks·08/19 02:07

  Major Investor Makes Bold Move on MapLight Therapeutics Stock

• TipRanks·08/17 12:57

  Morgan Stanley Keeps Their Hold Rating on MapLight Therapeutics, Inc. (MPLT)

• TipRanks·08/17 07:34

  MapLight Therapeutics announces $150M private placement

• TipRanks·08/16 13:23

  MapLight Therapeutics price target lowered to $31 from $35 at Raymond James